D.A. Davidson & Co. Beam Therapeutics Inc. Transaction History

D.A. Davidson & Co.

$12 Billion
Q3 2024

A detailed history of D.A. Davidson & Co. transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, D.A. Davidson & Co. holds 53,847 shares of BEAM stock, worth $1.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

53,847

Previous 49,625 8.51%

Holding current value

$1.3 Million

Previous $1.16 Million 13.51%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$22.57 - $33.14 $95,290 - $139,917	4,222 Added 8.51%	53,847 $1.32 Million
Q2 2024 Jul 31, 2024	BUY	$21.22 - $32.66 $120,359 - $185,247	5,672 Added 12.9%	49,625 $1.16 Million
Q1 2024 May 13, 2024	BUY	$23.46 - $45.07 $133,158 - $255,817	5,676 Added 14.83%	43,953 $1.45 Million
Q4 2023 Feb 09, 2024	BUY	$17.69 - $30.76 $207,539 - $360,876	11,732 Added 44.2%	38,277 $1.04 Million
Q3 2023 Nov 08, 2023	BUY	$23.01 - $32.46 $191,466 - $270,099	8,321 Added 45.66%	26,545 $638,000
Q2 2023 Aug 10, 2023	BUY	$29.32 - $35.99 $66,380 - $81,481	2,264 Added 14.19%	18,224 $581,000
Q1 2023 Apr 25, 2023	BUY	$30.15 - $48.79 $118,248 - $191,354	3,922 Added 32.58%	15,960 $488,000
Q4 2022 Feb 03, 2023	SELL	$36.73 - $51.6 $12,561 - $17,647	-342 Reduced 2.76%	12,038 $470,000
Q3 2022 Nov 07, 2022	BUY	$39.79 - $70.31 $11,738 - $20,741	295 Added 2.44%	12,380 $590,000
Q2 2022 Jul 28, 2022	BUY	$29.86 - $62.36 $13,556 - $28,311	454 Added 3.9%	12,085 $468,000
Q1 2022 May 12, 2022	BUY	$53.73 - $82.16 $71,622 - $109,519	1,333 Added 12.94%	11,631 $666,000
Q3 2021 Nov 15, 2021	BUY	$84.37 - $133.6 $868,842 - $1.38 Million	10,298 New	10,298 $896,000

Others Institutions Holding BEAM

# of Institutions

236

Shares Held

75.2M

Call Options Held

438K

Put Options Held

232K

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.7B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.

Account